For a patient discharged on warfarin after a deep vein thrombosis, the clinic is aiming for an international normalized ratio of
2.0 to 3.0. This is the standard therapeutic window for most indications requiring oral vitamin K antagonist therapy, including venous thromboembolism.
Warfarin works by inhibiting vitamin K–dependent clotting factors (II, VII, IX, X), and the INR reflects how much those factors have been suppressed. Without anticoagulation, the INR is approximately
1.0. An INR below
2.0 means the clotting cascade is not sufficiently inhibited, leaving the patient vulnerable to thrombus extension or a new embolic event. Conversely, an INR above
3.0 progressively increases the risk of major or life-threatening bleeding.
The cited study compared three INR target ranges—
1.5–2.5,
2.0–3.0, and
2.5–3.5—in patients with venous thromboembolism treated with warfarin. The authors reported no significant differences in recurrent VTE among the three ranges, which reinforces that the conventional
2.0–3.0 target remains an appropriate and widely accepted balance.
Key point! A lower range such as
1.5–2.0 may be considered in selected patients at very high bleeding risk, but it is not the standard initial target for deep vein thrombosis.
From a nursing perspective, weekly INR monitoring is appropriate during the early discharge period because warfarin has a narrow therapeutic index and its effect is influenced by dietary vitamin K intake, liver function, drug interactions, and adherence. The nurse should teach the patient that the goal is not a single number but a stable value within
2.0–3.0 on consecutive checks.
| INR range | Clinical interpretation | Nursing implication |
|---|
| 1.0–1.5 | Essentially no therapeutic anticoagulation | Inadequate protection; dose may need to be increased |
| 1.5–2.0 | Subtherapeutic for most VTE indications | Monitor closely; assess for signs of thrombus progression |
| 2.0–3.0 | Therapeutic target for deep vein thrombosis | Maintain dose; continue routine monitoring |
| 3.5–4.5 | Supratherapeutic; high bleeding risk | Hold or reduce dose per protocol; assess for bleeding |
Watch out! The patient lives alone and prepares his own meals, so dietary counseling is essential. Large, inconsistent amounts of vitamin K–rich foods such as leafy greens can cause the INR to fluctuate even when the warfarin dose is unchanged. The nurse should emphasize consistency in dietary vitamin K intake rather than complete avoidance.
Bleeding precautions should be reviewed at every encounter: use a soft toothbrush, avoid intramuscular injections when possible, report dark tarry stools, hematuria, unusual bruising, or prolonged bleeding from minor cuts. The patient should also be instructed to carry identification indicating warfarin use and to inform all healthcare providers, including dentists, before any procedure.
Because the patient will have weekly INR checks at the outpatient clinic, the nurse should reinforce that the dose may be adjusted based on each result, and that the patient should not self-adjust the dose between visits.
A single out-of-range value does not necessarily indicate treatment failure; trends over two or three consecutive checks guide dosing decisions.